Evotec nominates preclinical candidate from dermatology partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
May 4, 2026 1:50 AM EDTJoint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines
Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise
HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ: EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multitarget drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at... More
